Patient-preferred Versus Vaginally Administered Capsules¹

Study design: Results of a prospective cohort study of 285 women receiving progesterone for IVF-ET or ICSI cycles. Patients received Crinone 8% (90 mg QD) or progesterone capsules used vaginally (200 mg TID). In both groups, progesterone support began on the day of oocyte retrieval and continued until the day the pregnancy test was performed or until week 12 in the case of pregnancy. Shown above are patient preference data from a questionnaire completed by 48 patients who had experience with progesterone capsules used vaginally and Crinone 8%.

Utrogestan® is manufactured by Laboratory Besins International. This product is marketed in the United States by Solvay Pharmaceuticals, Inc., as Prometrium®.

Reference: 1. Simunic V, Tomic V, Tomic J, Nizic D. Comparative study of the efficacy and tolerability of two vaginal progesterone formulations, Crinone 8% gel and Utrogestan capsules, used for luteal support. Fertil Steril. 2007;87:83–87.